Eli Lilly
LLY NYSE· Pharmaceuticals
Last close · Oct 26, 2026
$1,279.14
KIRA · Stoqly’s AI analyst, in plain words
- Eli Lilly had $65.2B of revenue in fiscal 2025, up 44.7% on the year before. Over five years, revenue changed +21.6% a year on average.
- Eli Lilly made $20.6B of net profit in fiscal 2025. From fiscal 2016 to 2025, diluted EPS grew 27.5% a year.
- Free cash flow was $9.0B in fiscal 2025, 13.8% of revenue.
- Eli Lilly returned $9.5B to shareholders in fiscal 2025, 106% of free cash flow. The diluted share count fell 0.5%.
- Eli Lilly owes $33.6B more than it holds in cash, about 1.2 years of operating profit.
Market cap
$1.14T
P/E
42.9x
Revenue
$65.2B
Net income
$20.6B
Free cash flow
$9.0B
Operating margin
—
Eli Lilly in 30 seconds · fiscal 2025
Are sales growing?
+44.7%
Yes. Sales grew 44.7% last year.
Does it make a profit?
31.7%
Yes. It keeps 31.7% of every sale as profit.
Does profit turn into cash?
13.8%
Yes. 13.8% of sales ends up as free cash.
Is debt under control?
1.2x
Keep an eye on it. Repaying its debt would take 1.2 years of operating profit.
How healthy are the accounts?
8 / 9
Solid. It passes 8 of 9 health tests.
How is the share priced?
42.9x
One share costs 42.9 times its yearly profit per share. Typical for its sector: 27.9x.
What Eli Lilly does
Eli Lilly discovers, develops, makes and sells medicines. It reports a single business segment, human pharmaceutical products. Its medicines treat diabetes, obesity, cancer, immune diseases such as psoriasis and ulcerative colitis, migraine and Alzheimer's disease. They are sold in approximately 90 countries and made at facilities in the United States, including Puerto Rico, and in Europe and Asia. A few products bring in most of its revenue. Mounjaro, for type 2 diabetes, and Zepbound, for obesity, accounted for 56 percent of total revenues in 2025. Together with Verzenio, Trulicity, Taltz and Jardiance, they made up 82 percent. In the U.S., most of its products are distributed through wholesalers, and three of them, McKesson, Cencora and Cardinal Health, each accounted for a significant percentage of its revenue. It also delivers select medicines to patients through LillyDirect, its direct-to-patient platform, which uses third-party pharmacies.
Biggest risks, in its own words
- Relying on a few products, especially Mounjaro and Zepbound, for much of its revenue.
- Government price controls and limits by insurers and others on what they pay for its drugs or who can get them.
- Losing patent protection, which can cause rapid and severe drops in a medicine's revenue.
- Safety or effectiveness concerns about its medicines that could hurt sales and its reputation.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 12, 2026
- Legal name
- ELI LILLY AND COMPANY
- CIK
- 0000059478
Eli Lilly · LLY
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $28.3B | $28.5B | $34.1B | $45.0B | $65.2B |
| Revenue growth | 15.4% | 0.8% | 19.6% | 32.0% | 44.7% |
| Gross margin | 74.2% | 76.8% | 79.3% | 81.3% | 83.0% |
| Net income | $5.6B | $6.2B | $5.2B | $10.6B | $20.6B |
| Net margin | 19.7% | 21.9% | 15.4% | 23.5% | 31.7% |
| Diluted EPS | $6.12 | $6.90 | $5.80 | $11.71 | $22.95 |
| Cash | |||||
| Cash from operations | $7.4B | $7.6B | $4.2B | $8.8B | $16.8B |
| Capital expenditure | $1.3B | $1.9B | $3.4B | $5.1B | $7.8B |
| Free cash flow | $6.1B | $5.7B | $792M | $3.8B | $9.0B |
| FCF margin | 21.4% | 20.1% | 2.3% | 8.4% | 13.8% |
| Dividends paid | $3.1B | $3.5B | $4.1B | $4.7B | $5.4B |
| Share buybacks | $1.3B | $1.5B | $750M | $2.5B | $4.1B |
| Share count change | −0.1% | −0.8% | −0.2% | 0.1% | −0.5% |
| Debt and strength | |||||
| Cash and short-term investments | $3.9B | $2.2B | $2.9B | $3.4B | $7.3B |
| Debt incl. finance leases | $16.7B | $16.3B | $25.3B | $33.8B | $40.9B |
| Shareholders' equity | $9.0B | $10.6B | $10.8B | $14.3B | $26.5B |
| Net debt / EBITDA | 1.6x | 1.6x | 2.6x | 2.0x | 1.2x |
| Current ratio | 1.2x | 1.1x | 0.9x | 1.2x | 1.6x |
| Interest coverage | 19.1x | 21.5x | 14.5x | 17.2x | 29.8x |
| Returns and quality | |||||
| Return on capital | 29.1% | 28.0% | 19.4% | 28.9% | 40.8% |
| Return on equity | 76.4% | 63.6% | 48.9% | 84.6% | 101.2% |
| Piotroski F-score | 5 | 7 | 5 | 6 | 8 |
| Altman Z'' | 2.2 | 2.0 | 1.3 | 2.3 | 3.8 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$2.6B
5 insiders
Of sales under plans
1%
$19.8M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Eli Lilly · LLY
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Similar companies
Each company’s latest fiscal year. Fiscal years end in different months, so periods don’t line up exactly.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score |
|---|---|---|---|---|---|---|---|
| Eli Lilly LLY | $1.14T | 44.7% | — | 13.8% | 40.8% | 42.9x | 8 |
| Merck MRK | $347.3B | 1.3% | — | 19.0% | 24.8% | 111.6x | 4 |
| Pfizer PFE | $169.8B | −1.7% | — | 14.5% | 7.3% | 39.2x | 6 |
| AstraZeneca AZN | $268.8B | 8.6% | 23.4% | 20.0% | 16.8% | — | 9 |
| Bristol Myers Squibb BMY | $126.2B | −0.2% | — | 26.7% | 15.2% | 13.6x | 8 |
Price compared with profit (P/E)
How many times its yearly profit per share one share costs. Higher means investors pay more for each unit of profit.
KIRA
At $1,279.14 a share, the company is worth $1.14T: 42.9 times its earnings of the last four quarters.
Eli Lilly grew sales faster than 4 of its 4 similar companies. Its P/E is higher than 2 of 3.
Source: SEC EDGAR XBRL filings (CIK 0000059478). Data updated October 9, 2026. For information only — not investment advice. Check the original filings before relying on any figure.